AIP
KRYS icon

Ameritas Investment Partners’s Krystal Biotech KRYS Stock Holding History

Ameritas Investment Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$531K Buy
2,055
+42
+2% +$11.2K 0.02% 823
2025
Q4 		$496K Sell
2,013
-59
-3% -$12.4K 0.02% 828
2025
Q3 		$366K Sell
2,072
-437
-17% -$65.4K 0.01% 941
2025
Q2 		$345K Hold
2,509
– – 0.01% 994
2025
Q1 		$452K Sell
2,509
-86
-3% -$14.5K 0.02% 856
2024
Q4 		$407K Buy
2,595
+82
+3% +$14.5K 0.01% 932
2024
Q3 		$457K Buy
2,513
+83
+3% +$16K 0.01% 877
2024
Q2 		$446K Buy
2,430
+274
+13% +$46K 0.02% 846
2024
Q1 		$384K Sell
2,156
-81
-4% -$11.3K 0.01% 916
2023
Q4 		$278K Buy
2,237
+90
+4% +$9.98K 0.01% 1074
2023
Q3 		$249K Buy
2,147
+362
+20% +$44.2K 0.01% 1047
2023
Q2 		$210K Buy
1,785
+78
+5% +$7.96K 0.01% 1101
2023
Q1 		$137K Hold
1,707
– – 0.01% 1316
2022
Q4 		$136K Buy
1,707
+147
+9% +$10.9K 0.01% 1376
2022
Q3 		$108K Hold
1,560
– – ﹤0.01% 1433
2022
Q2 		$102K Hold
1,560
– – ﹤0.01% 1495
2022
Q1 		$104K Buy
1,560
+154
+11% +$9.61K ﹤0.01% 1627
2021
Q4 		$98K Hold
1,406
– – ﹤0.01% 1693
2021
Q3 		$73K Hold
1,406
– – ﹤0.01% 1892
2021
Q2 		$96K Buy
1,406
+254
+22% +$17.7K ﹤0.01% 1746
2021
Q1 		$89K Hold
1,152
– – ﹤0.01% 1746
2020
Q4 		$69K Hold
1,152
– – ﹤0.01% 1789
2020
Q3 		$50K Buy
1,152
+236
+26% +$10.2K ﹤0.01% 1835
2020
Q2 		$38K Hold
916
– – ﹤0.01% 1996
2020
Q1 		$40K Hold
916
– – ﹤0.01% 1785
2019
Q4 		$51K Buy
916
+143
+18% +$7.01K ﹤0.01% 1913
2019
Q3 		$27K Hold
773
– – ﹤0.01% 2226
2019
Q2 		$31K Buy
+773
New +$25.3K ﹤0.01% 2186

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameritas Investment Partners's KRYS Position: Q1 2026 in Review

Ameritas Investment Partners increased its Krystal Biotech (KRYS) stake by 2.1% in Q1 2026, buying an estimated $11.2K and bringing the position to 2,055 shares worth $531K. The position accounts for 0.02% of the portfolio, ranked #823.

Ameritas Investment Partners first reported a position in KRYS in Q2 2019 and has held it in 28 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Ameritas Investment Partners held 2,055 shares of Krystal Biotech worth $531K as of Q1 2026.
  • Ameritas Investment Partners bought 42 Krystal Biotech shares in Q1 2026, an estimated $11.2K.
  • Krystal Biotech made up 0.02% of Ameritas Investment Partners's portfolio in Q1 2026, its #823 holding.
  • Ameritas Investment Partners first reported a position in Krystal Biotech in Q2 2019 and has held it in 28 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.